Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Masayuki Ueno

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

M. Ueno, H. Takabatake, M. Sue, T. Kayahara, Y. Morimoto, M. Mizuno

Author affiliations

  • Department Of Gastroenterology And Hepatology, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4891

Background

Stereotactic body radiation therapy (SBRT) has been shown to have high efficacy to early-stage hepatocellular carcinoma (HCC) and is expected as an alternative to radiofrequency ablation (RFA). However, how liver function is impaired by SBRT, an important factor in the therapy for HCC, is uncertain. In this study, we compared the impact of SBRT on liver function and that of RFA.

Methods

We retrospectively analyzed 140 patients with single small (≤3 cm) hepatocellular carcinoma treated with SBRT or RFA between January 2014 and January 2019 in Kurashiki Central Hospital. A median age was 75 years, and 101 patients were male. Liver function was assessed by the albumin-bilirubin (ALBI) score before treatment (pre-ALBI) and 3 months after treatment (post-ALBI). Patients in the SBRT group were matched at a 1:1 ratio with patients treated with RFA by using propensity score method, and post-ALBI scores were compared between the two groups.

Results

Among the 140 patients, 42 and 98 patients were treated with SBRT and RFA, respectively. Before matching, patients in SBRT group were significantly older than patients in RFA group (78 vs. 72.5 years, p =.038), while patients’ sex, etiology of liver diseases, tumor size, tumor location and baseline liver function (both ALBI score and Child-Turcotte-Pugh score) were similar between the two groups. In SBRT group, median pre-ALBI and post-ALBI scores were -2.40 and -2.30, respectively, and the difference was not significant (p =.336). After propensity score matching, all the baseline characteristics were well balanced, and post-ALBI scores were not significant different between SBRT and RFA groups (-2.27 vs. -2.30, p =.828).

Conclusions

In our study, the impact of SBRT on liver function was comparable to that of RFA. Our findings help to promote SBRT as an expecting alternative treatment for early-stage HCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.